Science ❯ Biotechnology ❯ Drug Development

Clinical Research

Phase 3 Trials Gene Therapy Cancer Treatment Therapeutic Proteins Phase 1 Trials Therapeutic Effects FDA-Approved Drugs Midstage Trials Innovations Biomarker Testing Innovative Therapies Seizure Medications

Altimmune Targets Second-Half 2026 Launch for Global Phase 3 MASH Trial

Fresh funding gives Altimmune runway through the planned 2029 readout.

Moderna, Merck Melanoma Vaccine Shows Durable Five-Year Benefit as Stock Hits 52-Week High

Wave Life Sciences Soars on Obesity Trial Signal as It Begins $250 Million Stock Offering

myTomorrows Raises $29 Million From Avego to Scale AI Platform for Pre-Approval Treatments

FDA Names George Tidmarsh Director of Center for Drug Evaluation and Research